Feb 3, 2025 · Safety concerns Keros observed in a Phase 2 trial triggered a stock selloff for what had been one of the sector’s most successful initial public offerings of the last four years, according to BioPharma Dive data. By Kristin Jensen • Dec. 12, 2024

Jan 2, 2025 · Verve’s aspirations are rooted in a precise form of CRISPR gene editing that allows it to switch off genes associated with high cholesterol. Its first clinical trial attempt showed “proof of principle,” establishing that base editing a gene called PCSK9 could sharply lower cholesterol in people who have genetically high levels.

Jan 2, 2024 · Pain drug studies are also notoriously difficult, as the trial goals are subjective measures that can be confounded by a placebo response. “Basically, pain is really hard,” Stifel analysts wrote. In early 2024, Vertex will release results from a pair of placebo-controlled studies and a third, single-arm trial, in different forms of acute ...

Jul 1, 2024 · Results from a Phase 3 trial of a drug called dapirolizumab pegol are expected shortly and, if positive, could give Biogen a much-needed win. Biogen developed the drug, which targets an immune cell protein called CD40L, with UCB and would jointly sell it if it were to reach the market. The trial focuses on the most common and serious type of lupus.

Jan 3, 2022 · Faced with conflicting clinical trial data, the FDA chose to clear Aduhelm based on how it is thought to work, elevating a long-debated and unproven disease hypothesis in the process. Over the course of 2022, study results from Roche and Eisai could offer supporting evidence for Aduhelm, its developer Biogen and the FDA, or throw the drug's ...

Nov 26, 2024 · Lilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity drug trial Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, a finding that could advantage Lilly …

Jun 21, 2021 · But there's plenty more in store over the next six months or so, with important clinical trial results still to come. A big moment for gene editing, for instance, is just around the corner. A closely watched antiviral drug could change how COVID-19 is treated.

Jun 28, 2023 · Promising results from this trial, both earlier and again at ASCO, have heightened anticipation for a larger Phase 3 trial J&J is running that pits the combination against Tagrisso. The outcome, expected later this year, could either cement Tagrisso’s incumbent status, or crown a new challenger to AstraZeneca’s drug.

Oct 14, 2024 · Applying CAR T-cell therapy in new clinical settings presents unique challenges. Worldwide Clinical Trials is at the forefront, partnering with drug development teams to map this new path forward. Sept. 16, 2024

Jun 12, 2024 · Clinical trial abstracts posted Thursday ahead of this year’s ASCO meeting give a peek at anticipated datasets from Immunocore, Merus, J&J and Merck & Co. By BioPharma Dive staff • Updated May 24, 2024